Terms: = Gastric cancer AND MYC, c-Myc, 4609, ENSG00000136997 AND Clinical Outcome
10 results:
1. Multi-dimension metabolic prognostic model for gastric cancer.
Feng W; Xu B; Zhu X
Front Endocrinol (Lausanne); 2023; 14():1228136. PubMed ID: 38144563
[TBL] [Abstract] [Full Text] [Related]
2. Doublecortin-like kinase 3 (DCLK3) is associated with bad clinical outcome of patients with gastric cancer and regulates the ferroptosis and mitochondria function in vitro and in vivo.
Cheng J; Tang YC; Dong Y; Qin RL; Dong ZQ
Ir J Med Sci; 2024 Feb; 193(1):35-43. PubMed ID: 37340227
[TBL] [Abstract] [Full Text] [Related]
3. Frequency Of Double Expressor Lymphoma In A Tertiary Care Hospital.
Hassan M; Khattak MT; Qamar MA; Javed S; Saeed SU
J Ayub Med Coll Abbottabad; 2021; 33(1):44-48. PubMed ID: 33774953
[TBL] [Abstract] [Full Text] [Related]
4. Steroid receptor-associated and regulated protein is a biomarker in predicting the clinical outcome and treatment response in malignancies.
Naderi A
Cancer Rep (Hoboken); 2020 Oct; 3(5):e1267. PubMed ID: 32706923
[TBL] [Abstract] [Full Text] [Related]
5. MUC16 mutation predicts a favorable clinical outcome and correlates decreased Warburg effect in gastric cancer.
Zhao H; Zhang L
Biochem Biophys Res Commun; 2018 Dec; 506(4):780-786. PubMed ID: 30389134
[TBL] [Abstract] [Full Text] [Related]
6. MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.
Venturutti L; Cordo Russo RI; Rivas MA; Mercogliano MF; Izzo F; Oakley RH; Pereyra MG; De Martino M; Proietti CJ; Yankilevich P; Roa JC; Guzmán P; Cortese E; Allemand DH; Huang TH; Charreau EH; Cidlowski JA; Schillaci R; Elizalde PV
Oncogene; 2016 Dec; 35(48):6189-6202. PubMed ID: 27157613
[TBL] [Abstract] [Full Text] [Related]
7. C-myc-activated long noncoding RNA CCAT1 promotes colon cancer cell proliferation and invasion.
He X; Tan X; Wang X; Jin H; Liu L; Ma L; Yu H; Fan Z
Tumour Biol; 2014 Dec; 35(12):12181-8. PubMed ID: 25185650
[TBL] [Abstract] [Full Text] [Related]
8. cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression.
Lucas CM; Harris RJ; Giannoudis A; Copland M; Slupsky JR; Clark RE
Blood; 2011 Jun; 117(24):6660-8. PubMed ID: 21490338
[TBL] [Abstract] [Full Text] [Related]
9. Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy.
Kim HK; Choi IJ; Kim CG; Kim HS; Oshima A; Yamada Y; Arao T; Nishio K; Michalowski A; Green JE
Pharmacogenomics J; 2012 Apr; 12(2):119-27. PubMed ID: 21173787
[TBL] [Abstract] [Full Text] [Related]
10. c-myc expression is related with cell proliferation and associated with poor clinical outcome in human gastric cancer.
Han S; Kim HY; Park K; Cho HJ; Lee MS; Kim HJ; Kim YD
J Korean Med Sci; 1999 Oct; 14(5):526-30. PubMed ID: 10576148
[TBL] [Abstract] [Full Text] [Related]
